Zomedica Corp (QB) (ZOMDF)

Zomedica's Assisi Loop(R) Products Designated "Fear Free(R)" as Alliance to Advance Low Stress Care and Pet Wellbeing Continues with Fear Free, LLC

Collaboration with Fear Free and Zomedica reinforces Assisi Loop tPEMF™ therapy as a low-stress option for pets. ANN ARBOR, MI / ACCESS...

Form 8-K - Current report

Zomedica Announces "Fourth Friday at Four" Webinar on June 26, 2026: The Five Pillars of Zomedica - Framework for Clinical Value and Shareholder Returns

June session to present the strategic framework behind every Zomedica product and investment decision, connecting pet care outcomes, veterinary...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association

Collaboration with USEA for Zomedica's PulseVet® shock wave system will increase brand awareness among Eventing enthusiasts. ANN ARBOR, MI...

Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market

May session to review Q1 2026 financial results alongside an investor-focused look at the companion animal market for veterinary technology and...

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity

Zomedica surpasses $8 million in first quarter revenue for the first time and delivers record year-over-year revenue for 21st straight quarter...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale

April session to take investors inside Zomedica's manufacturing operations - showcasing quality systems, automation, and teams driving scalable...

Form PRE 14A - Other preliminary proxy statements

Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform

Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive...

Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity

Zomedica surpasses $10 million in quarterly revenue for the first time and delivers record year-over-year revenue for 20th straight quarter. ANN...